RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares ...

<?xml encoding="utf-8" ?> Editor’s note: This story and headline have been corrected to reflect that BNT122 is a BioNTech and ...

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and ...

Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Merck (MRK) stock climbed 10% to new highs after Phase 3 cancer vaccine trial success with Moderna. Analysts project $3B in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far. Merck (NYSE:MRK | MRK Price Prediction) ...